Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression
Open Access
- 17 August 2023
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 166, 115317
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82003989)
This publication has 26 references indexed in Scilit:
- PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer CellsPLOS ONE, 2014
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K InhibitionClinical Cancer Research, 2013
- STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domainProceedings of the National Academy of Sciences, 2013
- Augmenting the Antitumor Effect of TRAIL by SOCS3 with Double-Regulated Replicating Oncolytic Adenovirus in Hepatocellular CarcinomaHuman Gene Therapy, 2011
- Anti-Inflammatory and Immunomodulatory Effects of Paeonia Lactiflora Pall., a Traditional Chinese Herbal MedicineFrontiers in Pharmacology, 2011
- PD‐L1 expression on tolerogenic APCs is controlled by STAT‐3European Journal of Immunology, 2010
- Management of Small Hepatocellular Carcinoma: A Review of Transplantation, Resection, and AblationAnnals of Surgical Oncology, 2010
- Paeoniflorin protects RAW 264.7 macrophages from LPS-induced cytotoxicity and genotoxicityToxicology in Vitro, 2009
- Regulation of Interferon‐γ During Innate and Adaptive Immune Responses2007
- PROTECTIVE EFFECT OF PAEONIFLORIN ON IMMUNOLOGICAL LIVER INJURY INDUCED BY BACILLUS CALMETTE‐GUERIN PLUS LIPOPOLYSACCHARIDE: MODULATION OF TUMOUR NECROSIS FACTOR‐α AND INTERLEUKIN‐6 mRNAClinical and Experimental Pharmacology and Physiology, 2006